ImCheck to Present Updated ICT01 Data with Unprecedented High Rates of Complete Remission in AML at the AACR Annual Meeting 2025
The AACR poster presentation will provide an update on the data in AML patients most recently presented at the American Society of Hematology (ASH) Annual Meeting 2024 showing that ICT01 administered ...
How does Acute Myeloid Leukemia affect mental health and emotional well-being in patients?
The journey of fighting Acute Myeloid Leukemia (AML) in India encompasses severe physical and emotional challenges for both ...
Science Daily2d
Leukemia News
Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...
Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment
Aptevo Therapeutics (NASDAQ:APVO) announced two additional frontline Acute Myeloid Leukemia (AML) patients have achieved ...
EQS-News: Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities
EQS-News: Eckert & Ziegler SE / Key word (s): Agreement/Incoming Orders Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities 25.03.2025 / 09:30 ...
Targeted Oncology13d
Actimab-A Triplet Trial Launches in Frontline AML
Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...
Yahoo Finance12d
Cantargia enrols first patient in trial of nadunolimab for AML and MDS
Swedish company Cantargia has enrolled the first patient in the Phase Ib/IIa trial of nadunolimab for treating individuals with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS).